Literature DB >> 1849990

Exacerbation of dideoxycytidine-induced neuropathy with dideoxyinosine.

S F LeLacheur1, G L Simon.   

Abstract

Dideoxycytidine (ddC) and dideoxyinosine (ddI) are nucleoside derivatives that exhibit antiretroviral activity against the human immunodeficiency virus (HIV). Both of these agents are under active investigation as potential therapies for patients with HIV infection. In addition, both drugs may be obtained for HIV-infected individuals who cannot tolerate zidovudine. A major focus of the research effort involving these agents has been to define their toxicities. Both agents may cause peripheral neuropathy. We wish to report a patient who developed severe neuropathy following the administration of ddI that was given shortly after the patient was removed from a clinical trial of ddI. The rapid development of toxicity indicates that this side effect is additive or synergistic for these agents.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1849990

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  6 in total

Review 1.  Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and use.

Authors:  G J Moyle; B G Gazzard; D A Cooper; J Gatell
Journal:  Drugs       Date:  1998-03       Impact factor: 9.546

Review 2.  Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection.

Authors:  J C Adkins; D H Peters; D Faulds
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

Review 3.  Drug interactions with antiviral drugs.

Authors:  A M Taburet; E Singlas
Journal:  Clin Pharmacokinet       Date:  1996-05       Impact factor: 6.447

Review 4.  Current knowledge and future prospects for the use of HIV protease inhibitors.

Authors:  G Moyle; B Gazzard
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

Review 5.  Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management.

Authors:  G J Moyle; M Sadler
Journal:  Drug Saf       Date:  1998-12       Impact factor: 5.606

Review 6.  Zalcitabine. A review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS).

Authors:  R Whittington; R N Brogden
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.